Transactions
May 7, 2002
INVESTORS INJECT DRUG PRODUCER WITH CAPITAL
Ribapharm Inc., a spinoff of ICN Pharmaceuticals Inc., went public April 12. Its initial public offering brought in $260 million. UBS Warburg managed the offering, while CIBC World Markets and SG Cowen were co-managers.
UBS Warburg managed the offering, while CIBC World Markets and SG Cowen were co-managers.
Costa Mesa's Ribapharm is a biotech firm that researches and develops anti-viral and cancer drugs. Its s...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In